



No. 12-184615- -00012-0000

Fecha: 2014-07-08 15:55:39 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 412 REPOSPRESRECU Folios: 23

As. 122.333

Señor

**DIRECTOR DIVISIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO**

E.

S.

D.

REF: Expediente No. **12 -184.615-** solicitud de patente de invención a favor de **TAIPEI MEDICAL UNIVERSITY**. Título: **COMPUESTOS DE HIDROXAMATO DE INDOLILO O INDOLINILO**.

RECURSO DE REPOSICIÓN

JUAN PABLO CADENA SARMIENTO, portador de la tarjeta profesional No. 57.492 del C.S.J., obrando como apoderado de la sociedad solicitante, manifiesto a usted que debidamente notificado de la Resolución No. 33043 del 26 de Mayo de 2014, interpongo contra ella en debido término, **RECURSO DE REPOSICIÓN**, para que sea revocada en su totalidad, y en su lugar se conceda el Privilegio de Patente, para el objeto de la solicitud en referencia.

Respaldo el RECURSO en los siguientes

HECHOS

1. La resolución arriba citada No. 33043 niega el Privilegio exclusivo de Patente de Invención para el objeto de la solicitud de la referencia, considerando que el capítulo reivindicatorio carece de novedad y nivel inventivo. Lo anterior, de acuerdo con las siguientes consideraciones.
- i. Determinación del Estado de la Técnica

Consultadas las fuentes de información con que se cuenta se encontraron los siguientes documentos, que anticipan el objeto de esta solicitud.

No	Documento	Título	Fecha de publicación
D5	WO2006101456	<i>"Bycyclic heterocycles hidroxamate compounds useful as Histone Deacetylase (HDAC) inhibitors"</i>	02/Septiembre/2006

Considera el examinador que la presente invención no cumple con el requisito de novedad y nivel inventivo en vista del documento D5.

RESUELVE

ARTÍCULO PRIMERO: Denegar la patente de invención a la creación titulada **"COMPUESTOS DE HIDROXAMATO DE INDOLILO O INDOLINILO"**

FUNDAMENTOS

Nos permitimos mostrar nuestro total desacuerdo frente a las todas y cada una de las objeciones de la Resolución No. 33043 toda vez que en dicho análisis no se demostró de manera concluyente que la invención carecía de novedad y nivel inventivo. A continuación, me permito desvirtuar todas y cada una de las afirmaciones de su Despacho en contra de la novedad y nivel inventivo de la invención y expuestas en la Resolución No. 33043.

Como primera medida, ponemos a su consideración un nuevo pliego reivindicatorio que consta de dieciséis (16) reivindicaciones, las cuales se encuentran debidamente sustentadas por las divulgaciones del capítulo descriptivo y no exceden en ningún momento el alcance de la invención previamente reclamada.

Con relación a dicho nuevo pliego reivindicatorio, es preciso destacar que el alcance de la reivindicación 1 fue modificado a fin de establecer una clara diferencia entre la invención allí descrita y el estado de la técnica, como se comentará más adelante, y que la reivindicación 8 fue retirada teniendo en cuenta la materia contenida en la reivindicación 7.

Por lo anterior, solicitamos se reconozca la total validez del mencionado pliego reivindicatorio, y de la mano con los argumentos que prosiguen, sea estudiada y reconocida la plena patentabilidad de la invención allí descrita.

Novedad

Afirma el señor Examinador que la reivindicación 1 carece de novedad en vista de las divulgaciones del citado documento D5, frente a lo cual nos permitimos manifestar nuestro total desacuerdo ya que dicho documento no anticipa ni divulga todas y cada una de las características técnicas que dan origen a la presente invención y, por tanto, no constituye sustento suficiente a tal objeción.

Sin embargo, con el fin de destacar aún más las diferencias de la presente invención en cuanto al estado del arte, nos permitimos mencionar que la materia contenida en dicha reivindicación 1 fue debidamente restringida y que, a partir de ello, es posible diferenciar con claridad la presente invención del estado de la técnica, evidenciando su total novedad.

Concretamente, notará el señor Examinador que dentro de las posibles definiciones del radical R_a , el término "alquilo" fue eliminado y el término "arilo" fue restringido a "fenilo", con lo cual se establece una caracterización clara y diferenciada con relación a las divulgaciones del citado documento D5.

En lo que respecta a dicha anterioridad, nos permitimos expresar que esta da a conocer un número extremadamente amplio de heterociclos bicíclicos de hidroxamato que se caracterizan por presentar la siguiente fórmula estructural:




Figura 1. Estructura general de los compuestos divulgados en D5.

Al analizar en detalle las enseñanzas de dicho documento D5 encontramos que a pesar de que el radical R^1 de la fórmula anteriormente ilustrada puede representar un grupo alquilsulfonilo o arilsulfonilo, y de que tales compuestos son útiles como inhibidores de la enzima histona deacetilasa (HDAC), resulta inapropiado relacionar la presente invención con dicho estado de la técnica por cuanto ninguno de los ejemplos descritos en el documento D5 revela un compuesto que comprenda una fracción de indolilo o indolinilo en donde:

- i. el átomo de nitrógeno se encuentra enlazado únicamente a $-SO_2R_a$; y
- ii. R_a representa un radical diferente de hidrógeno tal como alquenilo, alquinilo, fenilo, heteroarilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, o heterocicloalquenilo.

Teniendo en cuenta que dicho documento D5 es completamente silencioso respecto a estas dos características técnicas –las cuales definen de manera particular y concreta el compuesto aquí reivindicado–, afirmamos que no hay lugar a objetarle falta de novedad al mismo, razón por la que la objeción del señor Examinador carece de total fundamento.

Así las cosas, solicitamos respetuosamente sea reconocido el cumplimiento del requisito de novedad por parte de la presente invención partiendo del hecho de que el documento D5 falla completamente en describir o ilustrar de manera específica el **compuesto de fórmula (I)** que aquí se reivindica.

Nivel inventivo

Por otra parte, considera su Despacho que las divulgaciones del ya comentado documento D5 constituyen instrucción o motivación suficiente para que el versado en la materia alcance los compuestos descritos en la reivindicación 13 sin necesidad de involucrar el uso de su capacidad inventiva. Debido a que la objetada reivindicación 13 es una reivindicación independiente, procedemos a demostrar el cumplimiento del requisito en mención por parte de la reivindicación 1, respectiva independiente.

Partiendo de nuestro total desacuerdo frente a la apreciación de su Despacho en torno al nivel inventivo de la presente invención, y retomando las diferencias expuestas previamente, es nuestra intención aclarar que el documento D5 carece de enseñanzas relativas al desarrollo de una molécula caracterizada porque el nitrógeno del anillo indol se enlaza de manera directa a un grupo SO_2R_a , en el cual R_a es alqueno, alquino, fenilo, heteroarilo, cicloalquilo, cicloalqueno, heterocicloalquilo, o heterocicloalqueno.

En contraste con tal caracterización, el documento D5 enseña una molécula en donde el sustituyente R_a corresponde a hidrógeno únicamente, lo cual evidentemente motivaría al versado en la materia a conservar tal caracterización en vista del favorable efecto derivado de la misma y lo alejara de la presente invención.

Así pues, consideramos que no hay ningún motivo por el cual sea posible afirmar que la presente invención podría haberse derivado de manera obvia a partir de las enseñanzas del documento D5, sobre todo teniendo en cuenta que éste resulta completamente silencioso respecto a los posibles sustituyentes que dan lugar al **radical R_a** reivindicado, y que los mismos se oponen a la caracterización propuesta por dicha anterioridad.

Debido a esto, consideramos que las divulgaciones del documento D5 no representan ningún tipo de aproximación a la materia reivindicada, ni serían de utilidad para el versado en la materia toda vez que no proporcionan información relacionada con la caracterización de la presente invención, más específicamente con la inclusión de un radical R_a correspondiente a alqueno, alquino, fenilo, heteroarilo, cicloalquilo, cicloalqueno, heterocicloalquilo, o heterocicloalqueno.

En ausencia del debido sustento, solicitamos sea reconsiderada la objeción en estudio toda vez que el documento D5 falla en poner a disposición del versado en la materia la información necesaria para que este alcance la presente invención de manera obvia, o en todo caso sin hacer uso de su actividad inventiva.

Adicional a lo anterior, cabe resaltar que la modificación estructural de una molécula constituye un campo de desafío permanente en el desarrollo de nuevas y mejores moléculas activas ya que, como bien reconocerá el señor Examinador, cualquier tipo de alteración a nivel del grupo farmacofórico de una molécula puede desencadenar efectos impredecibles como lo son el aumento, conservación e incluso pérdida de la actividad biológica, sin tener en cuenta la posibilidad de desencadenar efectos adversos y toxicidad.

En este orden de ideas, es nuestro interés acentuar el hecho de que no existe ninguna modificación estructural que pueda ser tildada de obvia o evidente, ya que es imposible prever el resultado farmacológico derivado de la inclusión, modificación o remoción de radicales o sustituyentes de una molécula teniendo en cuenta el especial rol que juega cada uno de dichos detalles al momento de establecer interacciones farmacocinéticas, farmacodinámicas y farmacológicas en un sujeto.

En consecuencia, afirmamos que aún si el versado en la materia optara por llevar a cabo modificaciones aleatorias con relación al radical R_a , este se enfrentaría a un sinnúmero de posibles modificaciones que evidentemente derivarían en un numeroso y diverso grupo de moléculas que difícilmente se asemejarían a la presente invención, y respecto a las cuales no se contaría con ninguna expectativa de éxito dada la incertidumbre que rodea el proceso de modificar estructuralmente una molécula activa.

De acuerdo con lo anterior, insistimos en que la objeción del señor Examinador carece de todo fundamento y solicitamos sea reconsiderada en vista de que no existen enseñanzas o divulgaciones en el campo técnico que insten a la persona normalmente versada en la materia al desarrollo de moléculas como las aquí descritas, o que brinden una expectativa de éxito razonable asociada a su caracterización específica.

Ahora bien, habiendo expuesto los argumentos relativos a la defensa del nivel inventivo de los compuestos reivindicados, nos permitimos agregar que la misma demuestra un **indicio adicional de nivel inventivo**, el cual procedemos a analizar a continuación y solicitamos sea tenido en cuenta como muestra contundente de la patentabilidad de la presente invención.

En este sentido, nos permitimos llamar la atención sobre el hecho de que los compuestos específicos divulgados por la presente solicitud exhiben una *eficacia superior e inesperada* en comparación con las moléculas que da a conocer el documento D5, tal y como se puede apreciar al comparar la Tabla 3 del documento D5 versus la Tabla 2 del capítulo descriptivo de la solicitud en estudio, las cuales dan a conocer información relativa al GI₅₀ (concentración del fármaco antitumoral que logra inhibir el crecimiento de células cancerígenas en un 50%) de los compuestos representativos de cada uno de dichos documentos.

Con el fin de sustentar lo anterior, presentamos a continuación un análisis comparativo de los resultados en las tablas ya mencionadas:

a. **Tabla 2.** Adaptada del capítulo descriptivo de la presente solicitud.

Estirpes celulares	A549	MDA-MB-231	Hep-3B	HA22T
	Pulmón	Mama	Hígado	Hígado
Nombre del compuesto	GI ₅₀ (µM)	GI ₅₀ (µM)	GI ₅₀ (µM)	GI ₅₀ (µM)
Compuesto 13	0.32	0.16	0.14	0.54
Compuesto 14	0.60	0.37	0.25	1.20
Compuesto 16	>10	>10	>10	>10
Compuesto 15	0.80	0.45	0.28	0.74
Compuesto 8	0.93	0.37	0.36	0.93
Compuesto 17	0.32	0.19	0.16	0.62
Compuesto 4	1.31	0.75	0.55	1.56
Compuesto 5	1.59	0.66	0.64	2.30
Compuesto 6	2.12	0.75	0.56	1.98
Compuesto 7	>10	>10	>10	>10
Compuesto 3	0.96	0.48	0.41	1.15
Compuesto 12	0.7	0.25	0.21	0.62
SAHA	2.37	0.97	0.69	2.24

b. Tabla 3. Adaptada del documento D5.

Compound No.	GI ₅₀ (Colo205) μ M	Compound No.	GI ₅₀ (Colo205) μ M
3	13	16	3.3
4	24	17	4.7
5	6.4	18	3.4
8	2.4	19	7.1
9	17	20	1.6
10	11	21	8.8
11	7.3	22	2.8
12	1.7	23	2.5
13	2.1	24	4.6
14	2.6	25	9.4
15	1.6		

Teniendo en cuenta la información consignada en las anteriores Tablas (**a. y b.**), es evidente que la magnitud de la GI₅₀ relacionada con los compuestos de la presente invención (**a. Tabla 2**) es significativamente menos que la relativa a los compuestos del documento D5, lo cual se asocia con una **eficacia superior** en términos de inhibición del crecimiento celular tumoral, lograda por la presente invención.

A partir de este hecho, solicitamos sea tenido en cuenta que, como consecuencia a la caracterización estructural que da lugar a los compuestos aquí reclamados, la presente invención demuestra un efecto técnico superior que, reiteramos, sirve de sustento adicional a favor de la patentabilidad de los mismos.

Sin embargo, con el único propósito de sustentar la superioridad y el aporte que simboliza la presente invención al campo técnico –para que consecuentemente se reconozca el pleno cumplimiento de los requisitos de nivel inventivo por parte de la misma–, anexamos al presente memorial el artículo científico titulado “*Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo*” (Huang et al. PLOS ONE, August 2012, Volume 7, Issue 8, pages 1 to 11) que proporciona datos experimentales adicionales con relación a la actividad anticancerígena de la molécula MPT0E028 equivalente al Compuesto 12 de la presente invención.

En este contexto, Huan et al. demuestra que la molécula MPT0E028 constituye un inhibidor de histona deacetilasa novedoso y potente basado en ensayos clínicos *in vitro* e *in vivo* empleando células humanas HCT116 de cáncer colorrectal, cuyos resultados se exponen en la siguiente tabla:

Tabla 1. Efectos anti-proliferativos de la molécula MPT0E028 ensayados en paneles de la línea celular NCI-60.

Adaptada de Huan et al. (anexo al presente memorial)

Panels	Cell Line	GI ₅₀ (M)	TGI (M)	LC ₅₀ (M)	Panel	Cell Line	GI ₅₀ (M)	TGI (M)	LC ₅₀ (M)
Leukemia	CCRF-CEM	1.65E-7	>1.00E-4	>1.00E-4	Melanoma	LOX IMVE	2.22E-7	7.18E-7	2.88E-6
	HL-60 (TB)	4.39E-7	>1.00E-4	>1.00E-4		MALME-3M	3.75E-8	9.07E-7	>1.00E-4
	K-562	1.15E-7	>1.00E-4	>1.00E-4		M14	1.79E-7	1.11E-6	6.45E-6
	MOLT-4	3.17E-7	>1.00E-4	>1.00E-4		MDA-MB-435	1.46E-7	7.06E-7	1.13E-5
	RPMI-8226	8.11E-8	>1.00E-4	>1.00E-4		SK-MEL-2	4.33E-7	3.89E-6	3.49E-5
	SR	6.01E-8	>1.00E-4	>1.00E-4		SK-MEL-28	4.06E-7	2.74E-6	>1.00E-4
Non-Small Cell Lung Cancer	A549/ATCC	2.30E-7	1.09E-6	9.03E-6	Ovarian Cancer	SK-MEL-5	1.36E-7	3.10E-7	7.05E-7
	EKVX	5.34E-7	>1.00E-4	>1.00E-4		UACC-257	1.27E-7	1.65E-6	>1.00E-4
	HOP-62	1.87E-7	1.06E-6	1.92E-5		UACC-62	7.16E-8	3.39E-7	1.66E-6
	HOP-92	2.10E-7	8.14E-7	1.80E-5		KGROV1	1.83E-7	5.33E-7	2.39E-6
	NCI-H226	1.24E-6	3.88E-6	1.90E-5		OVCAR-3	2.33E-7	9.33E-7	7.30E-6
	NCI-H23	1.88E-7	9.22E-7	3.84E-6		OVCAR-4	5.09E-7	3.18E-5	>1.00E-4
	NCI-H322M	1.86E-7	1.14E-5	>1.00E-4		OVCAR-5	6.02E-8	3.16E-7	2.58E-6
	NCI-H460	1.44E-7	1.66E-6	2.16E-5		OVCAR-8	1.21E-7	1.75E-6	>1.00E-4
Colon Cancer	NCI-H522	1.67E-7	8.45E-7	1.30E-5	Renal Cancer	NCI/ADR-RES	3.85E-8	2.39E-7	>1.00E-4
	COLO 205	1.28E-7	2.64E-7	5.46E-7		SK-OV-3	1.90E-7	6.01E-7	4.26E-6
	HCC-2998	1.94E-7	5.22E-7	2.06E-6		786-O	3.00E-7	1.33E-6	4.02E-6
	HCT-116	5.63E-8	2.04E-7	5.66E-7		A498	2.43E-7	1.13E-6	5.13E-6
	HCT-15	4.30E-7	1.31E-5	9.02E-5		ACHN	1.67E-7	5.76E-7	4.08E-6
	HT29	1.18E-7	7.16E-7	6.81E-5		CAKI-1	2.18E-7	9.59E-7	>1.00E-4
	KM12	2.86E-7	1.49E-6	5.78E-6		RXF 393	1.12E-7	3.34E-7	9.98E-7
	SW-620	1.47E-7	1.12E-5	>1.00E-4		SN12C	4.58E-7	1.02E-5	>1.00E-4
CNS Cancer	SF-268	4.64E-7	3.40E-6	7.04E-5	Prostate Cancer	TK-10	1.03E-7	6.60E-7	3.36E-5
	SF-295	6.03E-8	3.40E-7	2.43E-6		UO-31	1.69E-7	1.46E-6	5.63E-6
	SF-539	2.41E-7	1.15E-6	3.39E-6		PC-3	2.40E-7	2.10E-5	>1.00E-4
	SNB-19	4.34E-7	1.64E-6	5.65E-6		DJ-145	1.79E-7	1.92E-6	>1.00E-4
	SNB-75	5.91E-8	6.27E-6	3.28E-5	Breast Cancer	MCF-7	2.30E-7	1.05E-5	6.27E-5
	U251	1.99E-7	8.20E-7	3.76E-6		MAD-MB-231/ATCC	2.41E-7	8.22E-7	2.04E-5
						HS-578T	2.53E-7	1.79E-5	>1.00E-4
						BT-549	6.80E-7	5.84E-6	>1.00E-4
						T-47D	1.21E-7	4.45E-7	>1.00E-4
						MDA-MB-468	1.96E-7	1.15E-6	6.31E-6

GI₅₀: 50% of growth inhibition;
TGI: total growth inhibition;
LC₅₀: 50% of lethal concentration.
M: Concentration in molar (M).
doi:10.1371/journal.pone.0043645.t001

Tal y como es posible apreciar, los resultados expuestos anteriormente revelan que la GI_{50} (COLO205) exhibida por la molécula MPT0E028 corresponde a **1.28E-7 M**, o dicho de otro modo, a **0.128 μM** , estando esta una concentración más de 10 veces por debajo de la lograda por las moléculas descritas en el documento D5, dentro de las cuales cabe resaltar que los Compuestos 15 y 20 –los más eficaces que da a conocer dicha anterioridad según los resultados expuestos en la Tabla 3 del documento D5 reproducida anteriormente– logran apenas una GI_{50} de 1.6 μM .

De la mano de este hecho, no se debe dejar de lado que los resultados experimentales alcanzados por la molécula MPT0E028 ensayada en otras líneas celulares de cáncer de colon (tales como HCC-2998, HCT-116, HCT-15, HT29, KM12 y SW-620, ilustradas en la Tabla descrita anteriormente) demuestran igualmente una inhibición significativa del crecimiento de células tumorales con **rangos de IG_{50} entre 0.0563 a 0.286 μM** , hecho que soporta aún más la superioridad que representa la presente invención como una alternativa terapéutica novedosa en el tratamiento del cáncer.

Adicionalmente, por si fuera poco, Huang et al. lleva a cabo una comparación adicional entre el compuesto SAHA (siglas en inglés del activo *suberoylanilide hydroxamic acid*, conocido también como vorinostat o Zolinza®) y la molécula MPT0E028 de la presente invención, encontrando que el tratamiento con esta última induce una inhibición más fuerte de las células cancerígenas ($GI_{50} = 0.82 \pm 0.07 \mu M$ y **$0.09 \pm 0.004 \mu M$** , respectivamente), lo cual se puede corroborar en la Figura 2A que reproducimos a continuación:




Figura 2. Adaptada de Huang et al. (anexo al presente memorial)

A la luz de lo anterior, solicitamos sea reconocido el beneficio que aporta la presente invención al campo técnico, la cual simboliza sin lugar a dudas una alternativa terapéutica de utilidad que alcanza resultados y efectos farmacológicos superiores y sorprendentes empleando concentraciones más bajas que las asociadas con las moléculas ya conocidas y que, a partir de ello, se demuestra **ventajosa** en comparación con el estado del arte.

Asimismo, solicitamos que las ventajas y efectos sorprendentes de la presente invención sean tenidos en cuenta como muestra adicional y contundente del cabal cumplimiento de los requisitos de novedad y nivel inventivo por parte de los compuestos reivindicados, los cuales insistimos son completamente meritorios del privilegio de patente que se solicita.

Por último, en complemento de lo dicho, nos permitimos afirmar que el señor Examinador no llevó a cabo un examen de nivel inventivo pertinente por cuanto omitió completamente las ventajas derivadas de la presente invención y se limitó a afirmar que la misma habría podido ser concebida sin dificultad por el versado en la materia a partir de lo divulgado en el documento D5, aun cuando las manifiestas diferencias existentes entre dicha anterioridad y la materia reclamada respaldan la patentabilidad de esta última.

Así las cosas, solicitamos sean sopesados todos y cada uno de los comentarios, evidencias y argumentos aquí expuestos, las cuales en compañía de un examen de patentabilidad objetivo y concienzudo, sustentan ampliamente la patentabilidad de los compuestos reivindicados en cumplimiento de los objetados requisitos de novedad y nivel inventivo.


PETICIÓN

Por las razones anteriormente expuestas, solicito a ese despacho **REVOCAR** la decisión tomada mediante la Resolución No. 33043 del 24 de Mayo de 2014 y tendiente a obtener la concesión del Privilegio de Patente de conformidad con los artículos 14 y 48 de la Decisión 486 de la comunidad Andina.

NOTIFICACIONES

Recibiré notificaciones en la Secretaría General de la Superintendencia de Industria y Comercio, o en su defecto, en mi oficina de Abogado, situada en la Calle 70ª No. 4-41 de esta ciudad de Bogotá.

Del Señor Director



JUAN PABLO CADENA SARMIENTO

T.P. No. 57.492 del C.S.J.

C.C. 80.410.337 de Usaquén

Calle 70 A No. 4 - 41

Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells *In Vitro* and *In Vivo*

Han-Lin Huang^{1,2}, Hsueh-Yun Lee^{2,3}, An-Chi Tsai³, Chieh-Yu Peng⁵, Mei-Jung Lai², Jing-Chi Wang³, Shioh-Lin Pan^{3,4*}, Che-Ming Teng^{1*}, Jing-Ping Liou^{2*}

1 Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan, **2** School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan, **3** Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan Town, Miaoli County, Taiwan, **4** Department of Pharmacology, Taipei Medical University, Taipei, Taiwan, **5** School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan

Abstract

Recently, histone deacetylase (HDAC) inhibitors have emerged as a promising class of drugs for treatment of cancers, especially subcutaneous T-cell lymphoma. In this study, we demonstrated that MPT0E028, a novel *N*-hydroxyacrylamide-derived HDAC inhibitor, inhibited human colorectal cancer HCT116 cell growth *in vitro* and *in vivo*. The results of NCI-60 screening showed that MPT0E028 inhibited proliferation in both solid and hematological tumor cell lines at micromolar concentrations, and was especially potent in HCT116 cells. MPT0E028 had a stronger apoptotic activity and inhibited HDACs activity more potently than SAHA, the first therapeutic HDAC inhibitor proved by FDA. *In vivo* murine model, the growth of HCT116 tumor xenograft was delayed and inhibited after treatment with MPT0E028 in a dose-dependent manner. Based on *in vivo* study, MPT0E028 showed stronger anti-cancer efficacy than SAHA. No significant body weight difference or other adverse effects were observed in both MPT0E028- and SAHA-treated groups. Taken together, our results demonstrate that MPT0E028 has several properties and is potential as a promising anti-cancer therapeutic drug.

Citation: Huang H-L, Lee H-Y, Tsai A-C, Peng C-Y, Lai M-J, et al. (2012) Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells *In Vitro* and *In Vivo*. PLoS ONE 7(8): e43645. doi:10.1371/journal.pone.0043645

Editor: Manfred Jung, Albert-Ludwigs-University, Germany

Received: March 20, 2012; **Accepted:** July 24, 2012; **Published:** August 22, 2012

Copyright: © 2012 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by a grant from the National Science Council of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jpl@tmu.edu.tw (JPL); apan0826@nhri.org.tw (SLP); cmteng@ntu.edu.tw (CMT)

These authors contributed equally to this work.

Introduction

Histone deacetylase inhibitors (HDACi) are a promising new class of anticancer agents. HDACi inhibit tumor progression through their ability to regulate gene expression by promoting acetylation of histone and non-histone proteins [1,2]. Currently, several HDACi, including SAHA, LBH589, PXD101, MS-275, and FK228, are being examined in clinical trials for their ability to treat various solid and hematological malignancies [3,4]. The U.S. Food and Drug Administration (FDA) recently approved SAHA and FK228 for the treatment of cutaneous T-cell lymphoma [5]. HDAC inhibitors (HDACi) modulate the expression of several genes that regulate apoptosis, angiogenesis [6,7], cell cycle progression, and cellular differentiation. They have minimal toxicity against normal cells [8–10]. Taken together, these findings are critical in designing target inhibitors of HDAC for the treatment of cancer and other diseases.

A close view of these clinical trials with small molecule HDACi indicated the hydroxamic acid or *N*-hydroxyacrylamide group play an important role in HDAC activity [11,12]. We previously reported identification of the indoline-1-sulfonamide-containing compounds with apparent anticancer activity [13,14]. On the basis of the observations above, we designed and synthesized a series of new class of histone deacetylase inhibitors. Among

them, 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-*N*-hydroxy-acrylamide (MPT0E028) has the best inhibitory activity of HDACs. In this study, we examined the antitumor activities of MPT0E028 in several cancer cell lines from the NCI-60 cancer cell panel. We investigated the effects of MPT0E028 on cell cycle progression and apoptosis and explored possible molecular mechanisms that underlie its anticancer activity. In addition, we examined the effect of MPT0E028 on the growth of human colorectal cancer HCT116 cells *in vivo*, using a tumor xenograft model, which confirmed the antitumor effect of MPT0E028. Our results suggest that MPT0E028 is a promising therapeutic candidate for the treatment of human cancers.

Materials and Methods

Materials

MPT0E028 and SAHA was synthesized by Dr. Jing-Ping Liou's Lab. (School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan), and the purity is more than 98% (Data S1). RPMI 1640, M199, fetal bovine serum (FBS), penicillin, streptomycin, and all other tissue culture reagents were obtained from Life Technologies (Grand Island, NY, USA). Antibodies against various proteins were listed as following: α -tubulin, PARP, actin, HRP-conjugated anti-mouse, and anti-rabbit IgG were from




Figure 1. The synthesis of MPT0E028. Reagents and conditions. (a) NaBH₃CN, AcOH, 0°C–r.t.; (b) (i) benzenesulfonyl chloride, pyridine, reflux; (ii) LiAlH₄, THF, 0°C–r.t.; (iii) pyridinium dichromate (PDC), molecular sieves, CH₂Cl₂, r.t.; (c) (i) methyl(triphenylphosphoryl)acetate, CH₂Cl₂, r.t.; (ii) 1 M LiOH(aq), dioxane, 40°C; (d) (i) NH₂OTHP, PYBOP, Et₃N, DMF, r.t.; (iii) trifluoroacetic acid, CH₃OH, r.t. Abbreviations: NaBH₃CN, sodium cyanoborohydride; AcOH, acetyl acid; LiAlH₄ (LAH), lithium aluminium hydride; THF, tetrahydrofuran; PDC, pyridinium dichromate; NH₂OTHP, O-(tetrahydro-2H-pyran-2-yl)hydroxylamine; PYBOP, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; Et₃N, triethylamine; DMF, dimethylformamide; TFA, trifluoroacetic acid.
doi:10.1371/journal.pone.0043645.g001

Santa Cruz (Santa Cruz, CA, USA); histone 3, actin, acetyl- μ -tubulin were from cell signaling were from Cell Signaling Technologies (Boston, MA, USA); caspase 3 was from Imgenex (San Diego, CA, USA); acetyl-histone 3 was from Upstate Biotechnology (Lake Placid, NY, USA). Propidium iodide (PI), sulforhodamine B (SRB), and all of the other chemical reagents were obtained from Sigma Chemical (St. Louis, MO, USA).

Cell Culture

The human colorectal cancer cell line HCT116, breast cancer cell line MDAMB231 and human umbilical vein endothelial cells (HUVEC) were purchased from American Type Culture Collection (ATCC; Manassas, VA). Ovarian cancer cell line NCI-ADR was obtained from the DTP Human Tumor Cell Line Screen (Developmental Therapeutics Program, NCI). HCT116, MDAMB231 and NCI-ADR cells were cultured in RPMI 1640 with 10% heat-inactivated fetal bovine serum (v/v) and penicillin (100 units/mL)/streptomycin (100 μ g/mL). HUVEC was cultured in M199 with 20% heat-inactivated fetal bovine serum (v/v) and penicillin (100 units/mL)/streptomycin (100 μ g/mL). All cells were maintained in a humidified incubator at 37°C in 5% CO₂/95% air.

NCI-60 Cell Lines Screening

The NCI-60 cancer cell lines screening was conducted by the NCI's Developmental Therapeutics Program (DTP; <http://www.dtp.nci.nih.gov/branches/btb/ivclsp.html>).

Sulforhodamine B Assay

HCT116, MDAMB231 and NCI-ADR cells were seeded in 96-well plates in medium with 5% fetal bovine serum overnight. Cells were fixed with 10% trichloroacetic acid representing cell population at the time of drug treatment (T_0). After incubation with vehicle (0.1% DMSO), MPT0E028 or SAHA for 48 h, cells were fixed with 10% trichloroacetic acid and then stained with sulforhodamine B at 0.4% (w/v) in 1% acetic acid. Excess Sulforhodamine B was washed away by 1% acetic acid and dye-containing cells were lysed with 10 mmol/L Trizma base. The absorbance was read under wavelength of 515 nm. By measuring time zero (T_0), control

growth (C), and cell growth in the presence of the drug (T_x), the percentage growth was calculated. Percentage growth inhibition was calculated as $100 - [(T_x - T_0)/(C - T_0)] \times 100$. Growth inhibition of 50% (GI₅₀) is determined at the drug concentration that results in 50% reduction of total protein increase in control cells during the compound incubation.

Crystal Violet Assay

The HUVECs were seeded into 96-well culture plates (5000 cells/well) in quadruplicate. After 24 h incubation, cells were fixed with 0.1% crystal violet/20% methanol, representing cell population at the time of drug treatment (T_0). Other cells were treated with MPT0E028 or SAHA for 48 h. After 48 h incubation at 37°C, cells were stained with 0.1% crystal violet/20% methanol for 10 minutes and washed for 3 times. Then the dye was eluted by 0.1 M sodium citrate/75% ethanol, and the absorbance is measured at 550 nm.

FACScan Flow Cytometry

After the treatment of vehicle (0.1% DMSO), MPT0E028 or SAHA for the indicated time courses, the cells were harvested by trypsinization, fixed with 75% (v/v) alcohol at 4°C overnight. After centrifugation, cells were incubated in 0.1 mol/L phosphate-citric acid buffer [0.2 mol/L NaHPO₄, 0.1 mol/L citric acid (pH 7.8)] for 20 min at room temperature. Then, the cells were centrifuged and resuspended with 0.5 mL PI solution containing Triton X-100 (0.1%, v/v), RNase (100 μ g/mL), and PI (80 μ g/mL). DNA content was analyzed with the FACScan and CellQuest software (Becton Dickinson).

HDAC Biochemical Assays

The HDACs *in vitro* activities of recombinant human HDAC 1, 2, 4, 6 and 8 (BPS Biosciences) were detected by fluorogenic release of 7-amino-4-methylcoumarin from substrate upon deacetylase enzymatic activity. Half maximal inhibitory concentration (IC₅₀) is determined at the drug concentration that results in 50% reduction of HDAC activity increase in control wells during the compound incubation.

Table 1. Anti-proliferative effects of MPT0E028 in the NCI-60 cell line panels.

Panels	Cell Line	GI ₅₀ (M)	TGI (M)	LC ₅₀ (M)	Panel	Cell Line	GI ₅₀ (M)	TGI (M)	LC ₅₀ (M)
Leukemia	CCRF-CEM	1.65E-7	>1.00E-4	>1.00E-4	Melanoma	LOX IMVE	2.22E-7	7.18E-7	2.88E-6
	HL-60 (TB)	4.39E-7	>1.00E-4	>1.00E-4		MALME-3M	3.75E-8	9.07E-7	>1.00E-4
	K-562	1.15E-7	>1.00E-4	>1.00E-4		M14	1.79E-7	1.11E-6	6.45E-6
	MOLT-4	3.17E-7	>1.00E-4	>1.00E-4		MDA-MB-435	1.46E-7	7.06E-7	1.13E-5
	RPMI-8226	8.11E-8	>1.00E-4	>1.00E-4		SK-MEL-2	4.33E-7	3.89E-6	3.49E-5
	SR	6.01E-8	>1.00E-4	>1.00E-4		SK-MEL-28	4.06E-7	2.74E-6	>1.00E-4
Non-Small Cell Lung Cancer	A549/ATCC	2.30E-7	1.09E-6	9.03E-6	Ovarian Cancer	SK-MEL-5	1.36E-7	3.10E-7	7.05E-7
	EKVX	5.34E-7	>1.00E-4	>1.00E-4		UACC-257	1.27E-7	1.65E-6	>1.00E-4
	HOP-62	1.87E-7	1.06E-6	1.92E-5		UACC-62	7.16E-8	3.39E-7	1.66E-6
	HOP-92	2.10E-7	8.14E-7	1.80E-5		IGROV1	1.83E-7	5.33E-7	2.39E-6
	NCI-H226	1.24E-6	3.88E-6	1.90E-5		OVCAR-3	2.33E-7	9.33E-7	7.30E-6
	NCI-H23	1.88E-7	9.22E-7	3.84E-6		OVCAR-4	5.09E-7	3.18E-5	>1.00E-4
	NCI-H322M	1.86E-7	1.14E-5	>1.00E-4		OVCAR-5	6.02E-8	3.16E-7	2.58E-6
	NCI-H460	1.44E-7	1.66E-6	2.16E-5		OVCAR-8	1.21E-7	1.75E-6	>1.00E-4
Colon Cancer	NCI-H522	1.67E-7	8.45E-7	1.30E-5	Renal Cancer	NCI/ADR-RES	3.85E-8	2.39E-7	>1.00E-4
	COLO 205	1.28E-7	2.64E-7	5.46E-7		SK-OV-3	1.90E-7	6.01E-7	4.26E-6
	HCC-2998	1.94E-7	5.22E-7	2.06E-6		786-0	3.00E-7	1.33E-6	4.02E-6
	HCT-116	5.63E-8	2.04E-7	5.66E-7		A498	2.43E-7	1.13E-6	5.13E-6
	HCT-15	4.30E-7	1.31E-5	9.02E-5		ACHN	1.67E-7	5.76E-7	4.08E-6
	HT29	1.18E-7	7.16E-7	6.81E-5		CAKI-1	2.18E-7	9.59E-7	>1.00E-4
	KM12	2.86E-7	1.49E-6	5.78E-6		RXF 393	1.12E-7	3.34E-7	9.98E-7
	SW-620	1.47E-7	1.12E-5	>1.00E-4		SN12C	4.58E-7	1.02E-5	>1.00E-4
CNS Cancer	SF-268	4.64E-7	3.40E-6	7.04E-5	Prostate Cancer	TK-10	1.03E-7	6.60E-7	3.36E-5
	SF-295	6.03E-8	3.40E-7	2.43E-6		UO-31	1.69E-7	1.46E-6	5.63E-6
	SF-539	2.41E-7	1.15E-6	3.39E-6		PC-3	2.40E-7	2.10E-5	>1.00E-4
	SNB-19	4.34E-7	1.64E-6	5.65E-6		DU-145	1.79E-7	1.92E-6	>1.00E-4
	SNB-75	5.91E-8	6.27E-6	3.28E-5	Breast Cancer	MCF-7	2.30E-7	1.05E-5	6.27E-5
	U251	1.99E-7	8.20E-7	3.76E-6		MAD-MB-231/ATCC	2.41E-7	8.22E-7	2.04E-5
						HS 578T	2.53E-7	1.79E-5	>1.00E-4
						BT-549	6.80E-7	5.84E-6	>1.00E-4
						T-47D	1.21E-7	4.45E-7	>1.00E-4
						MDA-MB-468	1.96E-7	1.15E-6	6.31E-6

GI₅₀: 50% of growth inhibition;
TGI: total growth inhibition;
LC₅₀: 50% of lethal concentration.
M: Concentration in molar (M).
doi:10.1371/journal.pone.0043645.t001

HeLa Nuclear Extract HDAC Activity Assay

The HeLa nuclear extract HDAC activity was measured by using the HDAC Fluorescent Activity Assay Kit (BioVision, CA, USA) according to manufacturer's instructions [15]. Briefly, the HDAC fluorometric substrate and assay buffer were added to HeLa nuclear extracts in a 96-well format and incubated at 37°C for 30 min. The reaction was stopped by adding lysine developer, and the mixture was incubated for another 30 min at 37°C. Additional negative controls included incubation without the nuclear extract, without the substrate, or without both. TSA at 1 μM served as the positive control. A fluorescence plate reader with excitation at 355 nm and emission at 460 nm was used to quantify HDAC activity. Half maximal inhibitory concentration (IC₅₀) is determined at the drug concentration that results in 50%

reduction of HeLa HDAC activity increase in control group during the compound incubation.

Total HDACs Enzymatic Activity Assay

Total HDACs enzyme activity was determined using the Boc-Lys(Ac)-AMC fluorometric HDAC activity assay kit (BioVision, Mountain View, CA, USA). HCT116 cells were treated with MPT0E028 and SAHA for 24 h. Cells were then collected and total cell lysates were analyzed using a Fluorometric HDAC Activity Assay Kit (k330-100; BioVision). A fluorescence plate reader with excitation at 355 nm and emission at 460 nm was used to quantify HDAC activity. Half maximal inhibitory concentration (IC₅₀) is determined at the drug concentration that




Figure 2. The effects of MPT0E028 on cell growth and cell cycle progression in human HCT116 cells. (A) Concentration-dependent effect of MPT0E028 and SAHA on cell growth. HCT116 cells were incubated without or with the indicated concentrations of MPT0E028 or SAHA for 48 h. Cell growth was evaluated by SRB assay. Data were expressed as mean $\pm$ S.E.M. of at least 3 independent experiments. (B) Concentration-dependent

effects of MPT0E028 and SAHA on cell cycle progression. HCT116 cells were treated without or with the indicated concentrations of MPT0E028 or SAHA for 24 h and were analyzed by flow cytometry for cell cycle distribution. (C, D) Data shown are the means of at least 3 independent experiments. (E) Time-dependent effects of MPT0E028 and SAHA on subG1 population. HCT116 cells were treated without or with 1 μ M MPT0E028 or SAHA for the indicated time interval and were analyzed by flow cytometry for subG1 population. (F) MPT0E028 induced-caspase 3 and PARP activation. HCT116 cells were treated without or with the indicated concentration of MPT0E028 or SAHA for 24 h subject to western blot for caspase 3 and PARP analysis. (G) MPT0E028 induced caspase-dependent cell apoptosis. HCT116 cells were treated without or with 3 μ M MPT0E028, SAHA or 20 μ M z-VAD-fmk for 24 h and subjected to western blot for caspase 3 and PARP analysis.

doi:10.1371/journal.pone.0043645.g002

results in 50% reduction of total HDAC activity increase in control group.

Western Blot Analysis

After the treatment of vehicle (0.1% DMSO), MPT0E028 or SAHA at indicated concentrations, cells were washed with chilled PBS. For total lysate, cells were lysed with the 120 μ L ice-cold lysis buffer [10 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L EGTA, 1 mmol/L phenylmethylsulfonyl fluoride, 10 μ g/mL aprotinin, 10 μ g/mL leupeptin, 1 mM sodium orthovanadate, 1 mM NaF, and 1% Triton X-100]. Cell lysates were centrifuged at 13,000 rpm for 30 min. For Western blot analysis, the amount of protein (40 μ g) was separated by electrophoresis in a 10% or 15% polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) membrane. After 1 h incubation at room temperature in PBS/5% nonfat milk, the membrane was washed with PBS/0.1% Tween 20, and incubated with the indicated antibodies at 4°C overnight. After washings with PBS/0.1% Tween 20, the corresponding secondary antibodies were applied to the membranes for 1 h at room temperature. The membranes were then washed with PBS/0.1% Tween 20 and the detection of signal was done with an enhanced chemiluminescence detection kit (Amersham, Buckinghamshire, UK).

In vivo Implantation and Tumor Growth

The human HCT116 colorectal adenocarcinoma cells used for implantation were harvested during log phase growth and resuspended in phosphate-buffered saline at 5×10^7 cells/mL. Each mouse was injected s.c. in the right flank with 1.0×10^7 cells (0.2 mL cell suspension). Tumors were monitored twice weekly and then daily as their volumes approached 1,200 mm³. Tumor size, in mm³, was calculated from: where w = width and l = length in mm of the tumor. Tumor volume = $(w^2 \times l)/2$. All animal experiments followed ethical standards, and protocols have been reviewed and approved by Animal Use and Management Committee of National Taiwan University (IACUC Approval No: 20100225).

Table 2. Activity of MPT0E028 and SAHA against HDACs.

Compound	HDAC1	HDAC2	HDAC8	HDAC4	HDAC6
	Class I			Class IIa	Class IIb
	IC ₅₀ (nM ± SE)				
MPT0E028	53.0 ± 12.0	106.2 ± 23.0	2532.6 ± 314.7	>10000	29.5 ± 6.4
SAHA	102.2 ± 22.1	336.2 ± 91.2	2898.9 ± 128.7	>10000	19.5 ± 3.1

HDAC activity was determined indirectly by measuring the fluorescence generated by a deacetylated fluorogenic peptide product (Materials and Methods). Data represent triplicate determinations from three independent experiments (mean ± SE). HDAC Class I isoforms: HDAC1, HDAC2, and HDAC8, HDAC Class II isoforms: HDAC4 and HDAC6.

doi:10.1371/journal.pone.0043645.t002

Mice

Female nude-athymic mice were 8 weeks old, and had a body weight (BW) range of 17.2–22.0 g, on D1 of the study. The animals were fed ad libitum water (reverse osmosis, 1 ppm Cl) and PicoLab Rodent Diet 20 Modified and Irradiated Lab Diet® consisting of 20.0% crude protein, 9.9% crude fat, and 4.7% crude fiber. The mice were housed on National Taiwan University Laboratory Animal Center, NTUMC, on a 12-hour light cycle at 21–23°C and 60–85% humidity.




Figure 3. Inhibition of HDACs activity by MPT0E028 and SAHA. (A) Inhibition of HDACs activity in HeLa nuclear extracts. Data were expressed as the mean of at least 3 independent experiments. (B) Inhibition of total HDAC activity by MPT0E028 and SAHA. HCT116 cells were treated with the indicated concentrations of MPT0E028 and SAHA for 24 h, and the nuclear proteins were isolated to determine the inhibition of total HDAC enzyme activity. Data are expressed as the mean ± S.E.M. of at least 3 independent experiments.

doi:10.1371/journal.pone.0043645.g003




Figure 4. Effect of MPT0E028 and SAHA on α -tubulin and histone H3 acetylation. (A) HCT116 cells were treated with MPT0E028 and SAHA for 24 h at the indicated concentrations. Cell lysates were prepared and subjected to SDS-PAGE and immunoblotting using acetyl-histone H3, histone H3, acetyl- α -tubulin, and α -tubulin antibodies. Quantitative analysis of western blot with ImageQuant (Molecular Dynamics, USA); acetyl-histone H3 (B) and acetyl α -tubulin (C) were analyzed in HCT116 cells. doi:10.1371/journal.pone.0043645.g004

Statistical and Graphical Analyses

The logrank test was used to determine the statistical significance of the difference between the TTE values of two groups, except any NTR deaths. Statistical and graphical analyses were performed with Prism 3.03 (GraphPad) for Windows. The two-tailed statistical analyses were conducted at $P=0.05$. Kaplan-Meier plots show the percentage of animals remaining in the study versus time. The Kaplan-Meier plots use the same data set as the logrank test.

The tumor growth curves show the group median tumor volume, on a log scale as a function of time. When an animal exits the study due to tumor size or TR death, the final tumor volume recorded for the animal is included with the data used to calculate the median at subsequent time points. Therefore, the final median tumor volume shown by the curve may differ from the MTV, which is the median tumor volume for mice remaining in the study on the last day (excluding all with tumors that have attained the endpoint). If more than one TR death occurs in a group, the tumor growth curves are truncated at the time of the last measurement that precedes the second TR death. Tumor growth curves are also truncated when the tumors in more than 50% of the assessable animals in a group have grown to the endpoint volume. (* $p<0.05$; ** $p<0.01$; *** $p<0.001$; compared with the respective control group).

In vitro Statistical Analysis

Data were expressed as mean $\pm$ SEM of the indicated number for separate experiments. Statistical analysis of data was performed with one-way ANOVA followed by the t test, and $p<0.05$ were considered significant. (* $p<0.05$; ** $p<0.01$; *** $p<0.001$; compared with the respective control group).

Results

The Synthesis of MPT0E028

The synthesis of MPT0E028 (1) is depicted in Figure 1. Commercially available methyl indole-5-carboxylate (2) was reacted with sodium cyanoborohydride in the presence of acetic acid afforded the methyl indoline-5-carboxylate (3) in 93% yield. The M -sulfonylation of indoline (3) with benzenesulfonyl chloride in pyridine and then $LiAlH_4$ -mediated C5-ester reduction, followed by the PDC oxidation produced the desired 1-benzenesulfonylindoline-5-carbaldehyde (4) in 42% yield (3 steps). Wittig reaction of methyl(triphenylphosphoranylidene)acetate with the indoline-5-carboxyaldehyde 4T and treatment of lithium hydroxide (LiOH) in MeOH gave cinnamic acid (5) in 73% yield. The conversion of carboxylic acid (5) to the hydroxamic acid (1) was accomplished in 72% yield by the treatment of NH_2OTHP in the presence of PYBOP and Et_3N , followed by trifluoroacetic acid-mediated deprotection. The detailed experimental information for the preparation of MPT0E028 is available in the supplemental section.

The Effect of MPT0E028 on Proliferation of Cancer Cell Lines

To determine whether MPT0E028 exhibits anti-cancer activity in human cancer cells, we tested the anti-proliferative activity of MPT0E028 using the NCI-60 cancer cell lines screening panel [16]. As shown in Table 1, MPT0E028 significantly inhibited cell proliferation in all human cancer cell lines examined at micromolar concentrations, but was especially potent in HCT116 cell line. Therefore, we chose HCT116 cells for further studies of the anti-cancer activity of MPT0E028 *in vitro* and *in vivo*.




Figure 5. The effect of MPT0E028 on the growth of HCT116 cells *in vivo*. All tumors grew to the 1,200-mm³ endpoint volume. (A) Tumors were measured regularly and growth delay was calculated for treatment groups relative to control tumors (TGD). (B) Kaplan-Meier survival analysis was based on the tumor growth endpoint. (C) Inhibition of tumor growth curves represented a mean±SEM and percentage change in mean tumor volume (percent TGI). (D) Body weights were measured daily during the first week and then 2 times per week. The body weight ratio was calculated relative to the baseline measurement. (E) *In vivo* effect of MPT0E028 on the expression of caspase 3, PARP, acetyl-histone H3 and acetyl- μ -tubulin in HCT116 xenograft tumors as determined by western blotting.
doi:10.1371/journal.pone.0043645.g005

MPT0E028 Significantly Induced HCT116 Cell Apoptosis

First, we demonstrated that MPT0E028 inhibits the growth of HCT116 cells in a concentration-dependent manner using SRB assay ($GI_{50}=0.09\pm0.004\text{ }\mu\text{M}$) (Figure 2A). Two other cell lines, MDA-MB-231 and NCI-ADR from the NCI-60 screening panel, were also chosen to analyze the sensitivity of MPT0E028 (MDAMB231, $GI_{50}=0.19\pm0.04\text{ }\mu\text{M}$; NCI-ADR, $GI_{50}=0.14\pm0.02\text{ }\mu\text{M}$). MPT0E028 also inhibited cell proliferation significantly in these two cell lines (Data S2A, S2B) but showed less sensitive compared to HCT116. We also determined the safety margin of MPT0E028 in human normal cells (e.g. HUVEC) and found that MPT0E028 show 20–40 folds less sensitive against normal cells ($GI_{50}=3.57\pm0.45\text{ }\mu\text{M}$), suggesting MPT0E028 specifically targets malignant tumor cells (Data S2C). To investigate the effect of MPT0E028 on cell cycle progression, cellular DNA content was measured by flow cytometry. We showed that treatment with MPT0E028 increased the number of cells in the sub-G1 phase of the cell cycle (Figure 2B and 2C). The reference compound was an HDACi, suberoylanilide hydroxamic acid (SAHA; vorinostat), with a GI_{50} of $0.82\pm0.07\text{ }\mu\text{M}$, which exhibited antiproliferative activity (Figure 2A) and induced apoptosis in HCT116 cells (Figure 2B and 2D) in a concentration-dependent manner but showed less effective compared to MPT0E028. As shown in Figure 2E, MPT0E028 also induced sub-G1 population in a time-dependent manner, while SAHA showed weaker effect and delayed cytotoxicity. MPT0E028 also induced caspase 3 and PARP activation in a concentration-dependent manner (Figure 2F). MPT0E028-induced apoptosis was abolished when cotreatment with caspase-inhibitor z-VAD-fmk, suggesting that MPT0E028 induced apoptosis through caspase-dependent pathway. These results suggested that MPT0E028 induced HCT116 cells cytotoxicity through the apoptosis pathway.

MPT0E028 is an Inhibitor of HDACs Activity

We next examined the effect of MPT0E028 on the activity of HDACs, using a panel of human recombinant HDAC proteins, and compared its activity to SAHA. As shown in Table 2, MPT0E028 significantly inhibited HDAC1 and HDAC2 from

class I as well as HDAC6 from class IIb at low nanomolar concentrations. While MPT0E028 was more potent than SAHA against recombinant HDAC1 and 2, it has little activity against recombinant HDAC4 and HDAC8, which is similar to the inhibitory pattern of SAHA. We confirmed that MPT0E028 inhibited nuclear HDAC activity in the cervical adenocarcinoma cell line HeLa ($IC_{50}=11.1\pm2.8\text{ nM}$) and in HCT116 cells ($IC_{50}=4.43\pm0.5\text{ }\mu\text{M}$), which were approximately 9–30 times more potent than SAHA ($IC_{50}=118.8\pm13.2\text{ nM}$ and $129.4\pm13.9\text{ }\mu\text{M}$, respectively) (Figure 3A and 3B). The potent HDACs inhibitory effect of MPT0E028 could also be observed in MDAMB231 and NCI-ADR cells (Data S3). These results suggested that MPT0E028 is a novel and potent HDAC inhibitor.

Effects of MPT0E028 on α -tubulin and Histone H3 Acetylation in HCT116 Cells

Because α -tubulin and histone H3 are common downstream targets of HDACs, we examined the effects of MPT0E028 on α -tubulin and histone H3 acetylation in HCT116 cells using western blot analysis. As shown in Figure 4, MPT0E028 induced stronger hyperacetylation of histone H3 than that of SAHA (Figure 4A and 4B), which is consistent with its potent inhibitory effect on class I HDAC1 and 2. In contrast, SAHA exhibited more potent α -tubulin acetylation than MPT0E028 (Figure 4A and 4C), suggesting that SAHA is more potent against class IIb HDAC6, which is consistent with our finding in Table 2.

MPT0E028 Inhibits Growth of Human Colon Cancer Xenografts *in vivo*

Finally, we evaluated the efficiency of MPT0E028 and SAHA using *in vivo* tumor HCT116 xenografts in a nude mice model (Figure 5A and 5B) (Table 3). Once a tumor was palpable with the size of approximately 55 mm³, mice were randomized into vehicle control and treatment groups (8 mice per group). Control mice received the vehicle (0.5% carboxymethyl cellulose +0.1% Tween 80). Tumors in all 3 groups were allowed to reach an endpoint volume of 1,200 mm³. The median time to endpoint (TTE) for control mice was 16.6 days. In mice that were orally treated with

Table 3. Treatment response summary for anti-cancer activity of MPT0E028 and SAHA in the human HCT116 colorectal cancer xenograft model.

Compound (n)	Dose (mg/kg)	Route	Schedule	Median TTE	T-C	%TGD	No. of CR	Logrank Significance	P value
Control (8)	–	po	qd to endpoint	16.6			0		
SAHA (8)	200	po	qd to endpoint	27.0	10	63%	0	*	0.0251
MPT0E028 (8)	200	po	qd to endpoint	36.9	20	122%	3	**	0.0031
MPT0E028 (8)	100	po	qd to endpoint	19.2	2.6	16%	1	ns	0.3084
MPT0E028 (8)	50	po	qd to endpoint	15.5			0	ns	0.7890

n = number of animals; Study Endpoint = 1200 mm³; Days in Progress = 60; TTE = time to endpoint; T-C = difference between median TTE (days) of treated versus control group; %TGD (tumor growth delay) = [(T-C)/C] × 100; CR = complete regression; Statistical Significance = Logrank test; ns = not significant; * = P < 0.05 compare with control. qd = once daily; po = oral administration.
doi:10.1371/journal.pone.0043645.t003

SAHA (200 mg/kg, daily), the TTE increased to 27.0 days, which corresponds to a T-C of 10.0 days and a percent tumor growth delay (TGD) of 63%. According to the logrank analysis, SAHA produced significant antitumor activity ($P=0.0251$). Oral treatment with MPT0E028 (200, 100, and 50 mg/kg, daily) increased the median TTE to 36.9, 19.2, and 15.5 days, respectively, corresponding to a T-C of 20, 2.6, and 0 days and a percent TGD of 122%, 16%, and 0%, respectively. Based on the logrank analysis, MPT0E028 exhibits significant antitumor activity at 200 mg/kg ($P=0.0031$). Notably, 3 mice in a group that were treated with 200 mg/kg MPT0E028 and 1 mouse in another group that was treated with 100 mg/kg MPT0E028 showed complete tumor regression after treatment (Table 3). In addition, mice were also dosed once a day for 15 days via oral administration to evaluate tumor growth inhibition after MPT0E028 treatment. We found that the growth of HCT116 cancer cells xenografts was suppressed by 73.5%, 32.0%, and 21.9% (percent tumor growth inhibition [TGI] values) after treatment with MPT0E028 at 200, 100, and 50 mg/kg, respectively, whereas SAHA at 200 mg/kg suppressed tumor growth by 47.7% (%TGI) (Figure 5C). No significant difference in body weight or other adverse effects were observed upon treatment with MPT0E028 (Figure 5D). We also determined the effect of MPT0E028 on the expression of caspase3, PARP, acetyl-histone H3 and acetyl- μ -tubulin *in vivo* in HCT116 xenograft tumor tissues. Mice were treated with 200 mg/kg MPT0E028 or SAHA for 7 days (oral, daily) and then tumors were carefully removed and subjected to western blot analysis. As shown in Figure 5E, caspase 3, PARP and acetyl-histone H3 were substantially induced in MPT0E028-treated group while acetyl- μ -tubulin were found more profoundly in SAHA-treated group, which is consistent with our finding *in vitro*. Taken together, MPT0E028 induced a dose-dependent delay and inhibition of tumor growth and displayed stronger anti-tumor activity *in vivo* than SAHA.

Discussion

HDACs are important targets for cancer therapy because of their ability to transcriptionally regulate the expression of genes that are involved in cell proliferation, differentiation, and apoptosis [17,18]. HDACi are currently in clinical trials for the treatment of solid tumors and in leukemia patients. Two HDACi, SAHA and FK228, have received the US FDA approval for the treatment of patients with cutaneous T-cell lymphoma. In this study, we report the synthesis of a new chemical compound 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-*N*-hydroxy-acrylamide (MPT0E028), that has a potent HDACi activity. MPT0E028 was designed based on our prior research with microtubule destabilizing agents using indoline-1-arylsulfonamides as a core structure [13,14]. After coupling an *N*-hydroxyacrylamide functional group at the 5-position of indoline ring, we afforded the desired MPT0E028.

Furthermore, we evaluated the anti-cancer activity of MPT0E028 *in vitro* and *in vivo*. We found that MPT0E028 induced cytotoxicity in numerous human cancer cell lines from the NCI-60 panels and performed mechanistic studies in HCT116 cells, which showed high sensitivity to MPT0E028. When compared to SAHA, treatment with MPT0E028 induced stronger inhibition of cancer cell ($GI_{50}=0.82\pm0.07\ \mu\text{M}$ and $0.09\pm0.004\ \mu\text{M}$, respectively) but not normal cell growth ($GI_{50}=3.57\pm0.45\ \mu\text{M}$) and produced a significantly higher number of sub-G1 (apoptotic) cells as determined by flow cytometry. Also, MPT0E028 induced more profoundly caspase 3 and PARP activation. Taken together, MPT0E028 inhibits cancer cells growth and induces apoptotic cell-death.

We demonstrated that MPT0E028 inhibits the activity of HDAC1, HDAC2 and HDAC8 in class I as well as HDAC6 in class IIb, but not HDAC4 in class IIa, and consistently induces acetylation of histone H3 and α -tubulin. Class I HDACs have been shown to be overexpressed in human colorectal cancer cells [19], which may contribute to perturbed cancer cell proliferation, differentiation, and apoptosis by both epigenetic or non-epigenetic modification [20,21]. Inhibition of HDAC activity induced the intrinsic and extrinsic apoptotic pathway, leading to cancer cell death [22,23]. In addition, HDACi could induce expression of p21 by stabilizing and inducing transcriptional activity of RUNX3, leading to induction of cancer cell apoptosis [24,25]. The inhibition of HDAC activity by MPT0E028 was 10–30 times stronger than that by SAHA in HeLa and HCT116 cells.

Finally, we examined the efficiency of MPT0E028 against the human HCT116 colorectal adenocarcinoma cell growth in mice. Median tumor growth and Kaplan-Meier curve analysis demonstrated strong antitumor activity of MPT0E028. Daily administration of MPT0E028 resulted in significant antitumor activity. Moreover, compared to SAHA, MPT0E028 displayed stronger anti-tumor activity. Based on these results, MPT0E028 is a novel synthetic HDACi with unique pharmacologic properties that should be tested in human colorectal cancer therapy.

In summary, we have identified a novel inhibitor of HDAC activity, MPT0E028, with antitumor activity *in vitro* and *in vivo*. The results presented here show that MPT0E028 inhibits HDACs activity and has antitumor properties that are more potent than SAHA, which is currently in clinical use in subcutaneous T-cell lymphoma. Thus, MPT0E028 is suitable for further testing as a novel anti-cancer agent.

Supporting Information

Data S1 Chemistry. Nuclear magnetic resonance (^1H NMR) spectra were obtained with Bruker DRX-500 spectrometer (operating at 500 MHz), with chemical shift in parts per million (ppm, δ) downfield from TMS as an internal standard. High-resolution mass spectra (HRMS) were measured with a JEOL (JMS-700) electron impact (EI) mass spectrometer. Flash column chromatography was done using silica gel (Merck Kieselgel 60, No. 9385, 230–400 mesh ASTM). All reactions were carried out under an atmosphere of dry nitrogen. **2,3-Dihydro-1H-indole-5-carboxylic acid methyl ester (3):** To a stirred solution of methyl indole-5-carboxylate (**2**) (0.30 g, 1.71 mmol) in AcOH (2 mL), sodium cyanoborohydride (0.16 g, 2.57 mmol) was added to the reaction mixture at 0°C. The reaction was warmed to room temperature and stirred for 2 h. The reaction was quenched with water at 0°C, concentrated NaOH was added up to pH 10. The aqueous layer was extracted with CH_2Cl_2 (15 mL $\times$ 3). The combined organic layer was dried over anhydrous MgSO_4 and concentrated under reduced pressure to give a yellow residue, which was purified by silica gel chromatography (EtOAc: *n*-hexane = 1:2) to afford **3** (0.28 g), yield 93%. ^1H NMR (500 MHz, CDCl_3): δ 3.06 (t, $J=8.5$ Hz, 2H), 3.65 (t, $J=8.5$ Hz, 2H), 3.84 (s, 3H), 6.53–6.55 (m, 1H), 7.75–7.76 (m, 2H). **1-Benzenesulfonyl-2,3-dihydro-1H-indole-5-carbaldehyde (4):** To a solution of **3** (0.28 g, 1.58 mmol) in pyridine (2 mL), benzenesulfonyl chloride (0.40 mL, 3.16 mmol) was added. The reaction mixture was refluxed overnight. The mixture was then purified by silica gel chromatography (EtOAc: *n*-hexane = 1:3) to afford the 1-benzenesulfonylindoline (0.40 g). ^1H NMR (500 MHz, CDCl_3): δ 2.99 (t, $J=8.6$ Hz, 2H), 3.87 (s, 3H), 3.97 (t, $J=8.6$ Hz, 2H), 7.45–7.48 (m, 2H), 7.56–7.59 (m, 1H), 7.66 (d, $J=8.5$ Hz, 1H), 7.75 (s, 1H), 7.82 (d, $J=7.7$ Hz, 2H), 7.90 (d, $J=7.9$ Hz, 1H). LAH (0.10 g,

2.52 mmol) was added to a solution of 1-benzenesulfonylindoline (0.40 g, 1.26 mmol) in THF (10 mL) at 0°C. The reaction mixture was warmed to room temperature and stirred for 2 h before it was quenched with water and then extracted with CH₂Cl₂ (15 mL×3). The combined organic layer was dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was further treated with PDC (0.63 g, 1.66 mmol)-mediated oxidation in the presence of molecular sieves (0.63 g) and CH₂Cl₂ (10 mL) stirring at room temperature overnight. The reaction mixture was filtered through celite and purified by silica gel chromatography (EtOAc: *n*-hexane = 1:2) to afford **4** (0.19 g, 42% yield). ¹H NMR (500 MHz, CDCl₃): δ 3.05 (t, *J* = 8.6 Hz, 2H), 4.01 (t, *J* = 8.7 Hz, 2H), 7.46–7.49 (m, 2H), 7.58–7.62 (m, 2H), 7.71 (d, *J* = 8.3 Hz, 1H), 7.75 (d, *J* = 8.3 Hz, 1H), 7.84 (d, *J* = 7.8 Hz, 2H), 9.85 (s, 1H). **3-(1-Benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-acrylic acid (5)**: To a solution of **4** (0.19 g, 0.66 mmol) in CH₂Cl₂ (10 mL) was treated with methyl (triphenylphosphoranylidene) acetate (0.27 g, 0.79 mmol). The reaction mixture was stirred at room temperature for 3 h, was then quenched with water, and extracted by CH₂Cl₂ (15 mL×3). The combined organic layer was dried over anhydrous MgSO₄ and concentrated under reduced pressure to give a yellow residue, which was then purified by silica gel chromatography (EtOAc: *n*-hexane = 1:3) to afford the acrylic acid methyl ester (0.20 g). 1 M LiOH aqueous solution (1.16 mL, 1.16 mmol) was added to a solution of acrylic acid methyl ester (0.20 g, 0.58 mmol) in dioxane (15 mL). The reaction mixture was stirred at 40°C overnight before it was concentrated under reduced pressure. The residue was dissolved in water and concentrated HCl was added up to acidic pH to give the precipitation, which was dried by vacuum to afford **5** (0.16 g, 73% yield). ¹H NMR (500 MHz, CD₃OD): δ 2.92 (t, *J* = 8.5 Hz, 2H), 3.96 (t, *J* = 8.5 Hz, 2H), 6.33 (d, *J* = 15.9 Hz, 1H), 7.38 (s, 1H), 7.41 (d, *J* = 8.5 Hz, 1H), 7.50–7.53 (m, 2H), 7.55 (d, *J* = 16.1 Hz, 1H), 7.58–7.64 (m, 2H), 7.82 (d, *J* = 7.6 Hz, 2H). **3-(1-Benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide (MPT0E028, 1)**: NH₂OTHP (0.05 g, 0.44 mmol) was added to a stirred solution of **5** (0.12 g, 0.37 mmol), PYBOP (0.20 g, 0.39 mmol), triethylamine (0.12 mL, 0.88 mmol) in DMF (1.5 mL). The reaction mixture was stirred at room temperature for 1 h before it was quenched with water, followed by extraction with EtOAc (15 mL×3). The

combined organic layer was dried over anhydrous MgSO₄ and concentrated under reduced pressure. The residue was purified by silica gel chromatography (CH₂Cl₂: CH₃OH = 30:1 : 1% NH₃(aq)) to give a white solid, which was treated with TFA (1.13 mL, 15.21 mmol) in the presence of CH₃OH (25 mL) and stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure to give a white residue, which was recrystallized by EtOAc/CH₃OH to afford compound **1** (0.09 g), 72% yield. mp: 162–164°C. ¹H NMR (500 MHz, CD₃OD): δ 2.91 (t, *J* = 8.5 Hz, 2H), 3.96 (t, *J* = 8.4 Hz, 2H), 6.32 (d, *J* = 15.8 Hz, 1H), 7.32 (s, 1H), 7.37–7.39 (m, 1H), 7.46 (d, *J* = 15.7 Hz, 1H), 7.50–7.53 (m, 2H), 7.58–7.64 (m, 2H), 7.82 (d, *J* = 7.8 Hz, 2H). MS (EI) *m/z*: 170 (100%), 344 (M⁺, 3.21%). HRMS (EI) for C₁₇H₁₆N₂O₄S (M⁺): calcd, 344.0831; found, 344.0829. (PDF)

Data S2 The effects of MPT0E028 on cell growth in human MDAMB231, NCI-ADR and HUVEC cells. Concentration-dependent effect of MPT0E028 and SAHA on cell growth in (A) MDAMB231, (B) NCI-ADR and (C) HUVEC cells. Cells were incubated without or with the indicated concentrations of MPT0E028 or SAHA for 48 h. Cell growth was evaluated by SRB and crystal violet assay. Data were expressed as mean ± S.E.M. of at least 3 independent experiments. (PDF)

Data S3 Inhibition of total HDAC activity by MPT0E028 and SAHA in MDAMB231 and NCI-ADR cells. (A) MDAMB231 and (B) NCI-ADR cells were treated with the indicated concentrations of MPT0E028 and SAHA for 24 h, and the total lysate were subjected to total HDAC enzyme activity detection. Data are expressed as the mean ± S.E.M. of at least 3 independent experiments. (PDF)

Author Contributions

Conceived and designed the experiments: HLH HYL SLP CMT JPL. Performed the experiments: HLH HYL SLP CMT JPL. Analyzed the data: HLH HYL ACT CYP MJL JCW. Contributed reagents/materials/analysis tools: HLH HYL ACT CYP MJL JCW SLP JPL. Wrote the paper: HLH SLP CMT JPL.

References

- Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. *Immunol Cell Biol* 90: 85–94.
- Beumer J, Tawbi H (2010) Role of histone deacetylases and their inhibitors in cancer biology and treatment. *Curr Clin Pharmacol* 5: 196–208.
- Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. *J Hematol Oncol* 3: 5.
- Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. *Clin Cancer Res* 15: 3958–3969.
- Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. *J Cell Biochem* 107: 600–608.
- Srivastava RK, Kurzrock R, Shankar S (2010) MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. *Mol Cancer Ther* 9: 3254–3266.
- Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. *Cancer Lett* 280: 145–153.
- Nishioka C, Ikezoe T, Yang J, Koeffler HP, Yokoyama A (2008) Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells. *Leukemia* 22: 2159–2168.
- Martínez-Iglesias O, Ruiz-Llorente L, Sánchez-Martínez R, García L, Zambrano A, et al. (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. *Clinical and Translational Oncology* 10: 395–398.
- Jazirehi AR (2010) Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. *Anticancer Drugs* 21: 805–813.
- Paris M, Porcelloni M, Binasci M, Fattori D (2008) Histone Deacetylase Inhibitors: From Bench to Clinic. *Journal of Medicinal Chemistry* 51: 1505–1529.
- Venugopal B, Evans T (2011) Developing histone deacetylase inhibitors as anti-cancer therapeutics. *Curr Med Chem* 18: 1658–1671.
- Chang J-Y, Hsieh H-P, Chang C-Y, Hsu K-S, Chiang Y-F, et al. (2006) 7-Arylaminoindoline-1-sulfonamides as a Novel Class of Potent Antitubulin Agents. *Journal of Medicinal Chemistry* 49: 6656–6659.
- Chang J-Y, Lai M-J, Chang Y-T, Lee H-Y, Cheng Y-C, et al. (2010) Synthesis and biological evaluation of 7-arylindoline-1-benzenesulfonamides as a novel class of potent anticancer agents. *MedChemComm* 1: 152.
- Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, et al. (2008) KD5170, a novel mercaptopketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. *Mol Cancer Ther* 7: 1054–1065.
- Paull K, Hamel E, Maalspeis L (1995) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute, in *Cancer Chemotherapeutic Agents*. In: Foye W, editor. Cancer chemotherapeutic agents. Washington, DC: American Chemical Society.
- Khosravi-Far R, White E, Shankar S, Srivastava RK (2007) Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis Programmed Cell Death in Cancer Progression and Therapy. Springer Netherlands. 261–298.
- Takai N, Narahara H (2007) Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. *Curr Med Chem* 14: 2548–2553.

New HDAC Inhibitor MPT0E028 for Colorectal Cancer

19. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, et al. (2007) Expression profile of class I histone deacetylases in human cancer tissues. *Oncol Rep* 18: 769–774.
20. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. *J Biol Chem* 281: 13548–13558.
21. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K-P, et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. *Cancer Cell* 5: 455–463.
22. Darvas K, Rosenberger S, Brenner D, Fritsch C, Gmelin N, et al. (2010) Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. *Int J Cancer* 127: 1384–1392.
23. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, et al. (2007) HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. *Int J Biochem Cell Biol* 39: 1500–1509.
24. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, et al. (2005) RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. *Mol Cell Biol* 25: 8097–8107.
25. Zopf S, Neureiter D, Boursalxis S, Abt T, Glaser K, et al. (2007) Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. *Int J Oncol* 31: 1391–1402.